 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3388 News |  |
| «12...1617181920212223242526...4849» |
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Modified Superposition in vitro Susceptibility of Aztreonam and Ceftazidime/Avibactam for an NDM-5 Metallo-β-Lactamase-Producing Klebsiella pneumoniae Isolate (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2303;
- Increase in the Occurrence of Carbapenem-Resistant Enterobacterales (CRE) in United States (US) Hospitals from 2019 to 2021 and Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against These Isolates (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2302;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales Collected from Patients with Bloodstream Infections (BSI) as Part of the ATLAS (India) Surveillance Program, 2019-2020 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2297;
- Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa isolates from United States Medical Centers (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2294;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Ceftazidime-avibactam Alone or as Combination Therapy? Multicenter Retrospective Cohort Analysis of Clinical Outcomes in Patients with Carbapenem-resistant Gram-negative Infection (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2290;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Ceftazidime/avibactam utilization in the national Veterans Affairs (VA) Healthcare System (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2289;
- Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2286;
- Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2281;
- In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2280;
- fosfomycin tromethamine / Generic mfg.
Pharmacokinetic/pharmacodynamic analysis of combination therapy with continuous infusion (CI) fosfomycin plus extended-infusion (EI) or CI beta-lactams for treating documented carbapenem-resistant Gram-negative bloodstream infections and/or hospital-acquired pneumonia: a case series (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2133;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2124;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Efficacy and Safety of Ceftazidime-Avibactam Comparative Dosage Regimens in Patients with Kidney Injury: A Retrospective Cohort Study (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2121;
- cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2105;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric Patients from US Medical Centers (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2025;
- Temporal Trends in Antibiotic Use of New β-lactams for Gram-Negative Bacteria with Difficult-to-Treat Resistance in the Southeastern United States (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1665;
- Benchmarking the Use of New β-lactams Utilizing a Novel Metric of Microbiological Burden (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1664;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1158;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Population Pharmacokinetics (PopPK) of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1157;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Financial and clinical impact of ceftolozane/tazobactam global recall on the treatment of multi-drug resistant Pseudomonas in a large health system (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1119;
- Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1045;
- Assessment of Antimicrobial Prescription Trends Based on AWaRe Index Among COVID Patients as part of the Implementation of a Modified Antimicrobial Stewardship Audit for COVID Locations of Restricted Access in a South Indian Tertiary Care Center (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_994;
- imipenem/relebactam / Merck (MSD)
Imipenem-Relebactam activity and genotypic characteristics of Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa Isolates from Latin American Infections - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017 – 2020 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_802;
- Gram Negative Bacteria with Increased Minimal Inhibitory Concentration for Cefiderocol among Pediatric Patients in a Northern Italy Hospital. (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_798;
- Vabomere (meropenem/vaborbactam) / Melinta Therap
Evaluation of Meropenem-Vaborbactam Susceptibility and Underlying Resistance Mechanisms among Clinical KPC-producing Klebsiella pneumoniae (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_796;
- Development of cefiderocol resistance in an Enterobacter hormaechei strain following prolonged antibiotic exposure (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_793;
- Vabomere (meropenem/vaborbactam) / Melinta Therap
Frequency of Carbapenemases in United States Hospitals (2016-2020) and Activity of Meropenem-Vaborbactam and Comparator Agents Tested Against These Isolates (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_780;
- Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations and Other b-lactam Agents (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_779;
- Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_778;
- OMNIvance (xeruborbactam) / Qpex Biopharma
Xeruborbactam (QPX) Potentiates the Activity of β-Lactam (BL) Antibiotics Against a Diverse Group of Highly Drug-Resistant Enterobacterales (ENT) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_777;
- OMNIvance (xeruborbactam) / Qpex Biopharma
Xeruborbactam (QPX) Potentiates the Activity of Multiple β-Lactams Against Highly Resistant Pseudomonas aeruginosa to a Greater Degree than Other β-Lactamase Inhibitors (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_776;
- Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_774;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Real-world Experience with Ceftazidime-avibactam Compared with Ceftolozane-tazobactam on Clinical Outcomes in Pseudomonas aeruginosa Infections (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_769;
- National Surveillance of Gram-negative Bacteria in Qatar, the Study for Monitoring of Antimicrobial Resistance Trends (SMART): from 2017 to 2019 (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_765;
- In Vitro Activity of Cefiderocol against IMP-Producing Enterobacterales Isolated in Japan (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_761;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_759;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America, ATLAS Global Surveillance Program 2018-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_749;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Pediatric Patients, ATLAS Global Surveillance Program 2017-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_748;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Adult Patients, ATLAS Global Surveillance Program 2017-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_747;
- aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie
Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) collected in Hospitals from Europe, Asia, and Latin America (2019-2021) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_728;
- aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_726;
- SPR206 / Spero Therap
In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_717;
- SPR206 / Spero Therap
Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_716;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020 (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_710;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Cost-Effectiveness Analysis of Introducing Ceftazidime-Avibactam to Treatment Strategies for Hospital-Acquired Infections in Greece (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2127;
Ceftazidime-avibactam demonstrated considerable cost-effectiveness against comparators for treating gram-negative HAIs, in Greece. As the value of new antimicrobials extend beyond those captured within this model, future methods should seek to estimate this additional value.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy Is Associated with Increased blaNDM-5 Copy Number and Gene Expression. (Pubmed Central) - Aug 31, 2022
Our patient's case suggests that increased copy numbers of bla NDM genes through translocation events is used by Enterobacterales to evade cefiderocol-mediated cell death. The frequency of increased NDM expression in contributing to cefiderocol resistance needs investigation.
- | Journal: Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). (Pubmed Central) - Aug 31, 2022
This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org/practice-guideline/amr-guidance/.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
PK/PD data, Preclinical, Journal: The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD). (Pubmed Central) - Aug 31, 2022
In a rat abdominal abscess model, therapy with ceftazidime or ceftazidime/avibactam (4:1 w/w) against blaKPC-2-positive K. pneumoniae resulted in 9.3 versus 3.3 log cfu/abscess, respectively, after 52 h. With respect to PK/PD, in Monte Carlo simulations, attainment of unbound drug exposure targets (ceftazidime fT>8 mg/L and avibactam fT>1 mg/L, each for 50% of the dosing interval) for the labelled dose of ceftazidime/avibactam (2 and 0.5 g, respectively, q8h by 2 h IV infusion), including dose adjustments for patients with impaired renal function, ranged between 94.8% and 99.6% of patients, depending on the infection modelled.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: The primary pharmacology of ceftazidime/avibactam: in vitro translational biology. (Pubmed Central) - Aug 31, 2022
Translation to efficacy against infections in vivo is reviewed in the second co-published article, Nichols et al. (J Antimicrob Chemother 2022; dkac172).
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Evolution of β-lactamase-mediated cefiderocol resistance. (Pubmed Central) - Aug 31, 2022
The expression of contemporary β-lactamase genes can potentially contribute to cefiderocol resistance development and the acquisition of mutations in these genes results in enzymes adapting to increasing cefiderocol concentrations. Resistance development caused clinically important cross-resistance, especially against ceftazidime and ceftazidime/avibactam.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Implementation of Chromatic Super CAZ/AVI medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral. (Pubmed Central) - Aug 31, 2022
Specificity was 86.8%. The Chromatic Super CAZ/AVI medium might be implemented in rectal swab surveillance cultures for identification of patients carrying CAZ-AVI-resistant organisms to contain the spread of these difficult-to-treat pathogens.